| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_143ac4fbe1e063c6a828a96cfffc34d5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-166
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate |
2014-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e4e420b3d23f0b1956414e1ef03217c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ffd384a89b6dc1544e17d51f6b38f6c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a8fe03dbddafa4ce69a225fe0e8bc095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30b4c124a7f8107b443d77c949021eb5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b231376d0a664327cc117fbdc854ca72 |
| publicationDate |
2014-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140041641-A |
| titleOfInvention |
Compositions of Controlled Release Oral Formulations Containing Itopride Hydrochloride and Methods for Making the Same |
| abstract |
The present invention relates to a method for preparing a sustained-release tablet containing itopride hydrochloride as an active substance. More specifically, the present invention relates to a method for preparing a sustained release tablet containing itopride hydrochloride as an active substance, And provides a sustained release that can improve compliance. The Ito-Pride sustained-release tablet according to the present invention can effectively control the release of itopride hydrochloride for 24 hours at a rate close to zero order without leaning deviation, thereby solving the inconvenience of eating three times a day once per day , Since the tablet size is small because the weight per tablet is 450 mg, the loss of medicinal efficacy and deterioration of symptoms can be prevented because the patient's compliance with the medicines is high. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190029997-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190029355-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190029996-A |
| priorityDate |
2014-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |